News

Boston Scientific, fully absorbable scaffold, FAST study, resorbable

Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective, single-arm...

Fantom, REVA Medical, FANTOM II trial, ACC

REVA Medical Inc. announced the initiation of patient enrollment in the FANTOM II clinical trial of its Fantom sirolimus-eluting bioresorbable scaffold in March. The scaffold, made from REVA's...

electronic stents, bioresorbable electronic stent, BES

With the recent innovation of flexible microelectronic sensor circuits that can be made from bioresorbable materials, it is now possible to create “electronic stents” to monitor a treated lesion...

ART, PBS, pure bioresorbable scaffold, CE Mark

Privately-held company Arterial Remodeling Technologies (ART) announced CE Mark clearance for its next-generation drug-free, pure bioresorbable scaffold used to treat coronary artery disease. The...

Boston Scientific, Synergy, EVOLVE I, EVOLVE II, EuroPCR 2015, results

Boston Scientific reported positive, long-term data from the EVOLVE Trial of the Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system, with no new major adverse...

Amaranth Medical, Fortitude BRS, MEND-II, RENASCENT, EuroPCR 2015

Amaranth Medical announced plans to report clinical results from the company's ongoing trial of its second-generation Fortitude sirolimus-eluting bioresorbable scaffold (BRS) at EuroPCR 2015. Juan...

Abbott, Absorb, dissolving stent, resorbable, CE Mark, Europe

Abbott announced that it has received CE Mark for the latest advancement of its Absorb stent system, called Absorb GT1. Absorb GT1 combines a fully dissolving stent with a next-generation delivery...

Boston Scientific, investors, cardiology, growth, expansion

Boston Scientific Corp. presented an overview of its continued business momentum and long-term growth strategies at a meeting with the investment community May 1.

Biotronik, DREAMS, BIOSOLVE-II trial, bioresorbable stent, magnesium

Biotronik announced the completion of enrollment in the BIOSOLVE-II trial — a clinical study investigating the safety and performance of DREAMS (DRug Eluting Absorbable Metal Scaffold).

MiStent SES, Micell Technologies, Europe, bioresorbable stents

Micell Technologies, Inc. announced the commercial availability of the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) in Europe. Stentys,...

Fantom, Reva Medical, Rutgers, bioresorbable stents

A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The State University of New Jersey, has been implanted in patients for the first time.

bioresorbable stents

Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely expected to overtake metallic stents in the coming years if the data trend...

stents, bioresorbable, clinical trial, clinical study

Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. 

Boston Scientific, EVOLVE II, Synergy, bioresorbable stent

In the first successful United States trial of a bioabsorbable polymer stent, the Boston Scientific Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system met its...

Stentys, coronary stent, MiStent SES, Micell Technologies Inc.

Micell Technologies Inc. announced commercialization plans for its MiStent Sirolimus Eluting Absorbable Polymer...

DAIC Editor Dave Fornell

The key take away messages from the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium were bioresorable stents and transcatheter valve technologies will likely...

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is more cost effective and offers a...

Amaranth Medical announced patient enrollment in multiple centers in Colombia, South America in MEND-II, a clinical trial to assess safety and feasibility of the company's Fortitude...

A first-of-its kind study comparing the safety and efficacy of biodegradable polymer sirolimus-eluting stents (BP-SES) to durable polymer sirolimus-eluting stents (DP-SES) found that the...

September 24, 2014 — A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS) with everolimus and biolimus eluting stents found that BVS demonstrated...